Study recruitment factors in advanced cancer: the Prognosis in Palliative care Study II (PiPS2) - a multicentre, prospective, observational cohort project

Anastasia K Kalpakidou, Chris Todd, Rumana Z Omar, Vaughan Keeley, Jane Griffiths, Karen Spencer, Victoria Vickerstaff, Karolina Christidoulides, Rachel Perry, Dafni Katsampa, Patrick Stone

ABSTRACT

Objectives The Prognosis in Palliative care Study II (PiPS2) was a large multicentre observational study validating prognostic tools in patients with advanced cancer. Many palliative care studies fail to reach their recruitment target. To inform future studies, PiPS2 rigorously monitored and identified any potential recruitment barriers.

Methods Key recruitment stages (ie, whether patients were eligible for the study, approached by the researchers and whether consent was obtained for enrolment) were monitored via comprehensive screening logs at participating sites (inpatient hospices, hospitals and community palliative care teams). The reasons for patients’ ineligibility, inaccessibility or decision not to consent were documented.

Results 17 014 patients were screened across 27 participating sites over a 20-month recruitment period. Of those, 4642 (27%) were ineligible for participation in the study primarily due to non-cancer diagnoses. Of 12 372 eligible patients, 9073 (73%) were not approached, the most common reason being a clinical decision not to do so. Other reasons included patients’ death or discharge before they were approached by the researchers. Of the 3299 approached patients, 1458 (44%) declined participation mainly because of feeling too unwell, experiencing severe distress or having other competing priorities. 11% (n=1841/17 014) of patients screened were enrolled in the study, representing 15% (n=1841/12 372) of eligible patients. Different recruitment patterns were observed across inpatient hospice, hospital and community palliative care teams.

Conclusions The main barrier to recruitment was ‘accessing’ potentially eligible patients.

Key messages

What was already known?
➤ Many studies don’t reach recruitment targets.
➤ Few previous studies have rigorously documented reasons for this.

What are the new findings?
➤ Main recruitment barrier is accessing potentially eligible patients.
➤ 56% of those approached, agree to enrolment.

What is their significance?
➤ Even very ill patients are willing to participate in research.
➤ Close monitoring of recruitment practices can inform future study designs.

Monitoring key recruitment stages may help to identify barriers and facilitators to enrolment and allow results to be put into better context.

Trial registration number ISRCTN13688211.

INTRODUCTION

Palliative care is assuming greater importance as people are living longer with multimorbidity and terminal illnesses. The number of patients with advanced cancer is anticipated to increase substantially over the next two decades. Undertaking research in palliative care is relevant and important to public health systems, such as the UK National Health Service (NHS), and is necessary to guide clinical practice.
Many palliative care studies fail to recruit adequately and on schedule\(^6\)\(^-\)\(^8\) and barriers to recruitment have been well documented.\(^6\)\(^-\)\(^9\) It is often difficult to identify eligible patients due to complex protocol designs, patients’ discharge or death before they can be seen by researchers and heavy symptom burden.\(^6\)\(^-\)\(^9\) Scarce research resources and insufficient training of research personnel to approach patients and caregivers\(^6\)\(^-\)\(^9\) have also been described as major barriers to recruitment in palliative care research. Additionally, a key obstacle to recruitment that is widely acknowledged is the phenomenon of ‘gatekeeping’, which refers to the reluctance of clinicians to allow access to patients for research purposes.\(^6\)\(^-\)\(^9\)

Our research group has previously reported on the factors that adversely affected recruitment to the Prognosis in Palliative care Study (PiPS), which was a large, national, multicentre, observational study that developed predictive models of survival for use in patients with advanced cancer.\(^10\)\(^\)\(^-\)\(^11\) Stone and coworkers\(^10\) identified the reasons why patients were or were not recruited at 18 sites, across different settings, including inpatient hospices, hospital and community palliative care teams. The results suggested that ‘gatekeeping’ may have acted as a barrier to recruitment. ‘Gatekeeping’ may stem from a well-intentioned desire to safeguard patients from burden, but it may deprive them of the opportunity to engage in autonomous decision-making about their own care.\(^12\)\(^-\)\(^13\) ‘Gatekeeping’ was found to occur least frequently in hospice inpatient settings.

The Prognosis in Palliative care Study II (PiPS2), was a national, multicentre, observational study to validate the PiPS prognostic models of survival, in a large independent cohort of patients with advanced cancer.\(^14\)\(^-\)\(^15\) Just as in the original study,\(^10\) we collected data relating to the challenges in identifying eligible patients, accessing and consenting them for participation. The main difference between this study and our previous report is that the PiPS2 patient sample represents a new and larger data set, recruited over a greater number of sites and using stricter data-quality control procedures, allowing for more robust evaluation of recruitment processes.

**METHODS**

**Study design**

PiPS2 opened to recruitment at 28 palliative care services across England and Wales. Patients were recruited from inpatient hospices, hospital and community palliative care teams.

**Study population and assessments**

Eligible patients were men and women, aged 18 years or over, who had locally advanced or metastatic incurable cancer and were no longer receiving treatment with curative intent. The study involved patients with or without capacity to consent to participate. Patients with capacity were required to provide a blood specimen for routine haematological and biochemical analysis. For patients without capacity, there was no requirement for blood sampling. As one of the conditions of research ethics committee approval, the research site team needed approval from clinical staff before approaching patients (or caregivers) about possible participation in the study. Data, which included clinical assessments, key symptoms and measures of disease extent, were usually obtained from a review of the medical notes and/or discussion with clinical staff. Data could also be obtained by direct questioning of patients with capacity.

All patients with capacity provided written informed consent. For patients without capacity, a personal consultee (a relative or a carer), who was designated as next of kin, provided assent by signing a declaration form. For patients with no next of kin, a nominated consultee (a member of clinical staff with no connection to the research) signed the declaration form, if they thought it appropriate.

Details about inclusion and exclusion criteria, study assessments and death notification have been published elsewhere.\(^14\)

**Recruitment monitoring**

To identify potential factors affecting recruitment, and to provide targeted support to the sites, if appropriate, recruitment was monitored using comprehensive screening logs (online supplemental appendix 1A), which were maintained at all participating sites. Logs recorded all patients who were referred to the service, so that they would be considered for inclusion in the study. However, because screening logs were anonymised, patients who were referred to the same service multiple times were allocated multiple screening ID numbers. Therefore, our data relate to ‘patient episodes’ rather than to ‘patients’.

Logs recorded patients’ age range, gender, capacity to consent, eligibility, whether they were approached by the research site team and whether consent was obtained for enrolment. Reasons for patients’ ineligibility, inaccessibility and refusal to consent, were also documented using a predetermined coding list (online supplemental appendix 1B) using the following categories:

1. Ineligibility—Non-cancer diagnosis, potentially curable cancer, under 18 years, insufficient English language skills, already in the study, not classified as ‘palliative’ patient (ie, expected to live more than a year).
2. Inaccessibility—Approach was deemed inappropriate by clinical staff (‘gatekeeping’), patient died or was discharged before review, patient previously refused study, patient was unavailable, personal or nominated consultee was unavailable, research staff were unavailable, other reasons.
3. Refusal to consent—No reason volunteered, patient unwilling to undergo venepuncture, other reasons.
Research site teams managed screening data on a day-to-day basis depending on the work schedule of research team members. They submitted screening logs for upload to the University College London (UCL) Data Safe Haven secure system once a week. At three participating sites, recruitment was supported by staff directly employed on the study grant. Research at other participating sites was supported by locally funded staff.

Given the large number of sites and screening data, it was not possible to review screening data in real time. It is possible that different sites coded reasons for ineligibility, inaccessibility or failure to consent, in different ways. Nonetheless, rigorous data quality control took place retrospectively, to identify missing data, discrepancies and duplicates.

To ensure high levels of consistency in return rates across sites, UCL central research team sent regular emails to sites to remind them to submit data. In case of delayed submissions, sites were contacted via email and/or telephone. Following data collection, grant-funded staff were re-deployed to carry out extensive data quality control on enrolled patient data; 100% of electronic case report forms (CRFs) were validated by comparing them against the paper CRFs.

**Statistical methods**

Descriptive statistics (proportions and percentages) were used to summarise data and were calculated using SPSS V.26. Statistical tests were not used for comparisons between groups because this was a descriptive rather than a hypothesis-testing study.

**RESULTS**

**Patient recruitment**

Twenty-eight sites opened to recruitment consisting of 17 inpatient units, 17 community teams and 6 hospital support services. Some sites offered more than one type of service. One site was unable to comply with study procedures and was therefore withdrawn.

Between August 2016 and April 2018, 17 014 patients were screened for eligibility across the 27 remaining sites (inpatient hospice, n=8074; hospital, n=3225; community, n=4260). Of these patients, 1841/3299 (56%) were subsequently approached in inpatient hospices (n=2089; hospital, n=192; community, n=1018). Of the 12 372 eligible patients, 3299 (27%) were accessed by the research site team across sites (inpatient hospice, n=8074; hospital, n=3225; community, n=4260). Of the 12 372 eligible patients, 1841/17 014 (11%) were enrolled in the study (inpatient hospice, n=1246; hospital, n=124; community, n=471).

Of the 17 014 patients, who were screened for eligibility, 12 372 (73%) individuals were eligible for inclusion (inpatient hospice, n=6520; hospitals, n=1592; community, n=4260). Of the 12 372 eligible patients, 3299 (27%) were accessed by the research site team and were informed about the study (inpatient hospice, n=2089; hospital, n=192; community, n=1018). Of these patients, 1841/3299 (56%) were subsequently enrolled in the study. Eight patients were withdrawn from the study, resulting in a final sample size of 1833. Patients’ flow through the recruitment process is shown in figure 1.

**Eligible versus ineligible patients**

The proportion of eligible patients was 81% (n=6520/8074) among hospice inpatients, 49% (n=1592/3225) in hospital palliative care services and 75% (n=4260/5715) in community settings.

The majority of eligible patients were between 55 and 84 years of age (75%, n=9226/12 372), 13% (n=1556/12 372) were below 55 years of age and 13% (n=1590/12 372) were above 84 years of age. Approximately 48% (n=5892/12 372) of eligible patients were women.

The most common reason for ineligibility was that the patient had a non-cancer diagnosis (n=3528/4644, 76%). This was more common in hospital patients (n=1489/1634, 91%) compared with patients in inpatient hospices (n=1027/1554, 66%) and community settings (n=1012/1256, 70%). Reasons why patients were regarded as being ineligible for the study are presented in table 1.

**Accessible versus inaccessible patients**

The research site team was able to approach and inform 27% (n=3299/12 372) of eligible patients about the study. The proportion of eligible patients who were accessible to the research site team differed across recruitment settings (32% (n=2089/6520) in inpatient hospice, 12% (n=192/1592) in hospital and 24% (n=1018/4260) in community); most patients were approached in inpatient hospice and least in hospital.

The proportion of accessible patients, who fell within the age range of 55–84 years, was 77% (n=2544/3299) (55–64 years of age: 18%, n=584/3299; 65–74 years of age: 31%, n=1015/3299; 75–84 years of age: 29%, n=945/3299). The proportion of accessible patients aged above 85 years and of those aged below 55 years was 12% (n=408/3299) and 11% (n=347/3299), respectively. These figures are broadly similar to the age distribution of eligible patients. A slightly higher proportion of accessible patients compared with inaccessible patients were women (49% (n=1623/3298) vs 47% (n=4269/9072)).

Eligible patients were not approached or informed about the study mainly due to clinical reasons. This was most common in inpatient hospices and least common in community patients (inpatient hospice 39% (n=1743/4434), hospital 34% (n=470/1400), community 22% (n=701/3248)). The second most common reason was that the patient died before they or their caregivers were informed about the study. Early death was more common in community patients (26%, n=1174/4434) compared with hospital patients (13%, n=181/1400).

A number of eligible patients were not accessed due to their discharge before being approached (17%, n=1532/9082) or unavailability of a researcher to provide information about the study within the specified time frame (14%, n=1242/9082). A number
of other unspecified reasons were reported (8%, n=726/9082). Based on research nurses’ notes, the most common other reasons included that the patient was imminently dying, feeling too unwell, extremely tired, emotionally distressed, unaware of their diagnosis or unwilling to discuss their illness because they were struggling to come to terms with it. Reasons why eligible patients could not be accessed by the research site team are presented in Table 2.

Enrolled versus unenrolled
Approximately 56% (n=1841/3299) of patients who were approached by the research site team and informed about the study, consented to participate. This represents 15% of all eligible patients (n=1841/12372). Fewer community patients consented (46%, n=471/1018) than inpatient hospice (60%, n=1246/2089) and hospital patients (65%, n=124/192).

Approximately 78% (n=1438/1841) of the enrolled patients were aged 55–84 years (55–64 years of age: 19%, n=349/1841; 65–74 years of age: 32%, n=583/1841; 75–84 years of age: 28%, n=506/1841), 11% (n=206/1841) were over 84 years of age and 11% (n=197/1841) were below 55 years of age. This was similar with the distribution of age groups among unenrolled patients; 55–84 years of age.

---

**Table 1** Reasons for ineligibility across palliative care settings

| Reason for ineligibility         | Inpatient hospice, n (%) | Hospital, n (%) | Community, n (%) | Total, n (%) |
|----------------------------------|--------------------------|----------------|-----------------|-------------|
| Non-cancer diagnosis             | 1027 (66)                | 1489 (91)      | 1012 (70)       | 3528 (76)   |
| Already in the study             | 306 (20)                 | 15 (<1)        | 107 (7)         | 428 (9)     |
| Not classified as ‘palliative’ * | 108 (7)                  | 59 (4)         | 174 (12)        | 341 (7)     |
| Insufficient English language    | 86 (5)                   | 24 (1)         | 138 (9)         | 248 (5)     |
| Curative cancer                  | 27 (2)                   | 41 (3)         | 25 (2)          | 93 (2)      |
| Under 18 years old               | 0 (0)                    | 6 (<1)         | 0 (0)           | 6 (<1)      |
| Total                            | 1554 (100)               | 1634 (100)     | 1456 (100)      | 4644 (100)† |

*Expected to live more than 1 year.
†Total number of ineligible patients, n=4642. For two patients there were more than one reasons for not being eligible for the study.
age: 76%, n=1106/1458 (55–64 years of age: 16%, n=235/1458; 65–74 years of age: 30%, n=432/1458; 75–84 years of age: 30%, n=439/1458); above 84 years of age: 14%, n=202/1458; below 55 years of age: 10%, n=150/1458. Gender distribution was comparable between enrolled and unenrolled patients (49% (n=894/1840) vs 50% (n=729/1458) were women, respectively).

Patients (and personal or nominated consultees) had no obligation to provide any reason for refusing consent and 477 patients did not volunteer a specific reason. A few (n=83) patients reported that they did not want to undergo venepuncture and 898 did not consent due other reasons. Based on researchers’ notes, these mainly included patients with extreme fatigue, distress or who were feeling too unwell. Of the 1841 enrolled patients, 8 were withdrawn either because they changed their mind regarding participation in the study (n=5) or due to other reasons (n=3).

**DISCUSSION**

To identify factors that may adversely affect recruitment, this study monitored three key stages of the recruitment process including the identification of eligible patients, the ability to access patients to discuss the study in detail and the proportion of participants who provided consent. This study found that 27% of all patients referred to the participating sites (n=4642/17014) were ineligible for the PiPS2 study, 73% of the eligible patients were inaccessible to the research site team (n=9082/12372) and that 44% of the patients or caregivers, who were approached and informed about the study declined to consent (n=1458/3299).

Overly restrictive eligibility criteria have previously been described as a major obstacle to recruitment to cancer and palliative care clinical studies.7 16–18 The main reason for patients’ ineligibility was a non-cancer diagnosis (21%, n=3528/17014). Although there is a growing recognition of the need to offer palliative care to patients without cancer,19 20 the majority of referrals to palliative care services still have cancer.21 Interestingly, we found that non-cancer diagnoses were more common among hospital rather than among hospice and community palliative care referrals, suggesting that hospital teams are providing more accessible services.

We found that eligible patients were inaccessible to the research site teams primarily due to ‘clinical reasons’ (24%, n=2914/12372). This category covered any reason why clinicians deemed patients’ approach as inappropriate and reflected the role of clinicians as gatekeepers to study participation. Other reasons for patients’ inaccessibility included unavailability of researchers (10%, n=1242/12372). Some of the eligible patients, who were not approached, such as those who died too quickly (18%, n=2224/12372) or were discharged (12%, n=1532/12372) before the research site team had the opportunity to approach them, could probably never have been enrolled in the study.

In both the original PiPS development study and in PiPS2, access to eligible patients was regulated by clinicians. Clinicians may prevent end-of-life patients from participating in research because of fear of burdening them or because of clinicians’ limited research expertise or the lack of a research-friendly culture, and doubts about the value or quality of the research.12 Although, we did not explicitly investigate the underlying

---

**Table 2** Reasons for inaccessibility across palliative care settings

| Reason for inaccessibility | Inpatient hospice, n (%) | Hospital, n (%) | Community, n (%) | Total, n (%) |
|----------------------------|--------------------------|----------------|----------------|-------------|
| Clinical reason            | 1743 (39)                | 470 (34)       | 701 (22)       | 2914 (32)   |
| Died before review         | 1174 (26)                | 181 (13)       | 869 (27)       | 2224 (24)   |
| Discharged before review   | 156 (4)                  | 402 (29)       | 974 (30)       | 1532 (17)   |
| Research staff unavailable | 958 (22)                 | 118 (8)        | 166 (5)        | 1242 (14)   |
| Other                      | 163 (4)                  | 176 (13)       | 387 (12)       | 726 (8)     |
| Previously refused study   | 103 (2)                  | 18 (1)         | 61 (2)         | 182 (2)     |
| Patient unavailable        | 60 (1)                   | 4 (<1)         | 74 (2)         | 138 (2)     |
| Consultee unavailable      | 77 (2)                   | 31 (2)         | 16 (<1)        | 124 (1)     |
| Total                      | 4434 (100)               | 1400 (100)     | 3248 (100)     | 9082 (100)* |

*Total number of inaccessible patients, n=9073. Eight patients were not approached for more than one reason.
reasons why clinicians deemed it inappropriate to approach some patients about this study, researchers’ notes suggested that eligible patients were sometimes not approached because clinical staff judged that they were imminently dying, were feeling too unwell or tired, were emotionally distressed or were unaware of their diagnosis. These may all be considered good reasons for ‘protecting’ patients from involvement in research. But it is relevant that imminent death or being too unwell were not exclusion criteria for the study, and such patients may have been eligible, and they (or their caregivers) may have been agreeable to their involvement in the study if only they had been approached and informed about it.

Many palliative care patients value their own autonomy and want to be able to make their own decisions about participation in research. Even in non-interventional studies (where there is seldom any direct benefit to participants) patients value the opportunity to be altruistic and to contribute to the community. Better education and training of clinicians in research methodology and use of structured frailty assessments have been proposed as ways to eliminate paternalistic clinician behaviours for patients’ protection.

The unavailability of research staff was another factor that affected the number of patients who were approached in PiPS2. Research staff are generally only available during office hours, and many staff only work part-time. However, most care occurs outside of office hours and at weekends. In the PiPS2 study, it was quite possible for patients to be admitted on a Friday afternoon and to have died or been discharged from the service before any research staff were back on duty. Similarly, when research staff were on annual leave or ill, it was not possible for patients to be recruited to the study. Hospices were affected more severely by staff unavailability compared with hospitals and community teams in the PiPS2 study possibly due to more limited resources, such as only having part-time research staff or limited cover for staff absences.

Most studies only report patients who are given participant information sheets as being potentially available for the study. In the PiPS2 study, we rigorously collected data on all referrals to the participating units throughout the duration of the research project (even when research staff were absent). This provided a greater appreciation of the potential pool of participants available for the study. However, in reality, limited resources meant that only a proportion of the total referrals could ever be considered for enrolment. Other studies have also highlighted the importance of access to sufficient and dedicated research personnel, while acknowledging that this would require greater investment. Consistent with existing literature, this study also identified that patients’ precipitous death or discharge were barriers to approaching them about participation in clinical research.

Approximately half of the patients (or their caregivers), who were informed about the study agreed to participate, this is in line with findings from other recent studies. Prior to conducting the study, we had been concerned that patients might refuse consent because of the need for a blood test. In fact, very few patients regarded this as a reason to decline to participate. Invasive procedures have previously been described as a barrier to recruitment in palliative care studies whereas simple non-invasive and non-drug studies have been acknowledged as being more attractive. Studies investigating strategies to improve accrual in palliative care studies have also emphasised the importance of using trained recruitment personnel, simplified consent processes, explanation of the meaningfulness of the research and expressing gratitude for patients’ time.

There were considerable differences in eligibility, accessibility and recruitment rates in different settings. We found that it was easiest to identify and approach eligible patients in hospices and hospital palliative care services, and that more hospice patients gave consent. In keeping with previous research, we found that recruitment of patients with advanced cancer in the community setting is extremely challenging. Higher rates of eligibility and accessibility to inpatient hospice patients may partly be explained by the fact that patients near the end of life, no longer undergoing curative treatment, are more likely to be found in hospices. On the other hand, a greater proportion of hospital patients may be willing to participate in research possibly because they are less ill than those in the hospice and are often supported by better research infrastructure. These findings may help guide other researchers about optimising recruitment strategies for their own studies.

**Strengths and limitations**

Most previous studies have only described the number of patients who are approached about the study and the proportion providing consent. Although this provides some understanding about the representativeness of the sample, it neglects to consider the majority of patients in most studies who are either ineligible or are never given the opportunity to consider participation. Our data set allows greater insight into the potential barriers and facilitators to research participation. However, given the large number of sites and potential participants that the PiPS2 study involved, it was not possible to systematically check the accuracy of the screening data and it is possible that different sites coded the reasons for ineligibility, inaccessibility or failure to consent, in different ways. Our data quality control procedures were time consuming and for this reason future studies that wished to rigorously collect such data would need to consider the resource implications on study funding. Our study also lacked a qualitative evaluation of ‘gatekeeping’, which would
have provided a richer understanding of the phenomenon of interest.

CONCLUSION

Many factors can affect recruitment to palliative care studies. In the PiPS2 study the key barrier was difficulty accessing potential research participants rather than refusal to consent. Although time-consuming and requiring extra resources to achieve, researchers should consider monitoring the key stages of recruitment (identifying eligible patients, approaching them about the study and obtaining consent) in order to identify barriers and facilitators to recruitment in their own studies and to allow research results to be put into better context.

Author affiliations

1 Marie Curie Palliative Care Research Department, University College London, London, UK
2 Faculty of Biology, Medicine and Health, The University of Manchester School of Health Sciences, Manchester, UK
3 Department of Statistical Science, University College London, London, UK
4 Palliative Medicine Department, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
5 Marie Curie Hospice Solihull, Solihull, UK

Acknowledgements We would like to thank the UCL PRIMENT Clinical Trials Unit and the University College Hospital London (UCLH) NIHR Biomedical Research Centre (BRC) for their support, and Dr Jane Harrington for her help with administrative tasks and data monitoring. We also would like to thank Peter Buckle and Dori-Anne Finlay for acting as Patient and Public Representatives for the study. We would finally like to thank all the patients who participated in this study and our collaborators across participating sites.

Contributors AKK was responsible for drafting the manuscript, coordinating data collection and the overall running of the research across participating sites. AKK also contributed to the generation of descriptive statistics. CT, VK, JG and RZO contributed to the conception and design of the study. RZO and VV were responsible for statistical consulting. KC, RP and DK were responsible for data monitoring procedures. KS was responsible for data collection and data monitoring procedures. PS led the conception and design of the study, applied for funding and drafted the study protocol. All authors read, critically revised and approved the final manuscript.

Funding This work was supported by the National Institute of Health Research (NIHR) Health Technology Assessment (HTA) Programme (Ref: 13/20/01); Professor Stone is supported by Marie Curie core funding (grant reference: MCCC-FCO-16-U).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study received ethical approval from the Yorkshire & the Humber - Leeds East Research Ethics Committee on 12 April 2016 (Ref: 16/YH/0132).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The study included de-identified participant data, which are available upon reasonable request from Professor Paddy Stone, who is the corresponding author.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Anastasia K Kalpakidou http://orcid.org/0000-0001-9453-9717
Victoria Vickerstaff http://orcid.org/0000-0002-3119-670X
Dafni Katampa http://orcid.org/0000-0002-7254-1653
Patrick Stone http://orcid.org/0000-0002-5765-9047

REFERENCES

1 Dahlin C. Clinical Practice Guidelines for Quality Palliative Care. In: The National consensus project for quality palliative care. 3 edn, 2013.
2 Stewart BW, Wild CP. World cancer report 2014. WHO, 2014:1–2.
3 Aoun SM, Kristjanson LJ. Challenging the framework for evidence in palliative care research. Palliat Med 2005;19:461–5.
4 Grande GE, Todd CJ. Why are trials in palliative care so difficult? Palliat Med 2000;14:69–74.
5 Buss MK, Arnold RM. Challenges in palliative care research: one experience. J Palliat Med 2004;7:405–7.
6 Hanson LC, Bull J, Wessell K, et al. Strategies to support recruitment of patients with life-limiting illness for research: the palliative care research cooperative group. J Pain Symptom Manage 2014;48:1021–10.
7 Unger JM, Vaidya R, Hershman DL, et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst 2019;111:245–55.
8 Unger JM, Cook E, Tai E, et al. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 2016;35:185–98.
9 Chen EK, Riffin C, Reid MC, et al. Why is high-quality research on palliative care so hard to do? barriers to improved research from a survey of palliative care researchers. J Palliat Med 2014;17:782–7.
10 Stone PC, Gwilliam B, Keeley V, et al. Factors affecting recruitment to an observational multicentre palliative care study. BMJ Support Palliat Care 2013;3:318–23.
11 Gwilliam B, Keeley V, Todd C, et al. Development of prognosis in palliative care study (PiPs) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ 2011;343:d4920.
12 Kars MC, van Thiel GJ, van der Graaf R, et al. A systematic review of reasons for gatekeeping in palliative care research. Palliat Med 2016;30:533–48.
13 White C, Hardy J. Gatekeeping from palliative care research trials. Prog Palliat Care 2008.
14 Kalpakidou AK, Todd C, Keeley V, et al. The prognosis in palliative care study II (PiPS2): study protocol for a multi-centre, prospective, observational, cohort study. BMC Palliat Care 2018;17:101.
15 Stone PC, Kalpakidou AK, Todd C. Prognosis in palliative care study II (PiPS2): a prospective observational validation study of prognostic tools with an embedded qualitative evaluation. Heal Technol Assessment Press, 2021.
16 Townsley CA, Selby R, Siiu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005;23:3112–24.
17 Ling J, Rees E, Hardy J. What influences participation in clinical trials in palliative care in a cancer centre? Eur J Cancer 2000;36:621–6.
18 Kim ES, Bruinoooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American

Kalpakidou AK, et al. BMJ Supportive Palliative Care 2021;0:1–8. doi:10.1136/bmjspcare-2020-002670
Original research

society of clinical oncology and friends of cancer research joint research statement. *J Clin Oncol* 2017;35:3737–44.

19 Department of Health. *End of life care strategy – promoting high quality care for all adults at the end of life*, 2008.

20 Alsop A. Collaborative working in end-of-life care: developing a guide for health and social care professionals. *Int J Palliat Nurs* 2010;16:120–5.

21 Alsop MJ, Ziegler LE, Mulvey MR, *et al.* Duration and determinants of hospice-based specialist palliative care: a national retrospective cohort study. *Palliat Med* 2018;32:1322–33.

22 Shelby-James T, Abernethy AP, Currow DC. Evidence in palliative care research: how should it be gathered? *Med J Aust* 2006;184:196–8.

23 White CD, Hardy JR, Gilshenan KS, *et al.* Randomised controlled trials of palliative care - a survey of the views of advanced cancer patients and their relatives. *Eur J Cancer* 2008;44:1820–8.

24 White C, Gilshenan K, Hardy J. A survey of the views of palliative care healthcare professionals towards referring cancer patients to participate in randomized controlled trials in palliative care. *Support Care Cancer* 2008;16:1397–405.

25 McWhinney IR, Bass MJ, Donner A. Evaluation of a palliative care service: problems and pitfalls. *BMJ* 1994;309:1340–2.

26 Schenker Y, Bahary N, Claxton R, *et al.* A pilot trial of early specialty palliative care for patients with advanced pancreatic cancer: challenges encountered and lessons learned. *J Palliat Med* 2018;21:28–36.

27 Filbet M, Schloss J, Maret J-B, *et al.* The use of complementary medicine in palliative care in France: an observational cross-sectional study. *Support Care Cancer* 2020;28:4403–12.

28 Ross C, Cornbleet M. Attitudes of patients and staff to research in a specialist palliative care unit. *Palliat Med* 2003;17:491–7.

29 LeBlanc TW, Lodato JE, Currow DC, *et al.* Overcoming recruitment challenges in palliative care clinical trials. *J Oncol Pract* 2013;9:277–82.

30 Edwards Z, Bennett MI, Petty D, *et al.* Evaluating recruitment methods of patients with advanced cancer: a pragmatic opportunist comparison. *Int J Pharm Pract* 2019;27:536–44.

31 Hayslip B, Leon J. *Hospice care*. Newbury Park, CA: Sage, 1992.

32 Hospice Info. What is hospice? Available: [http://www.hospiceinfo.org/what-is-hospice/](http://www.hospiceinfo.org/what-is-hospice/) [Accessed 12 Jun 2020].

33 Davidson TSG. *End of life evidence review*, 2013.